In a report entitled "Results of the Nonclinical Toxicology Laboratory Good Laboratory Practices Pilot, Compliance Program," the FDA has released a summary of the initial 42 inspections performed under the proposed Good Laboratory Practices Regulations.
The overall objectives of the pilot program were to ascertain if the proposed GLP's were realistic and/or attainable while at the same time evaluate the current state of laboratory practices in industrial, contract and university (but not governmental) facilities.
The major emphasis of the report centers on how well existing laboratories conformed to the original check-list criteria prepared by the FDA.
The selection of laboratories tested was based on facilities typical to the regulatory jurisdiction of each FDA Bureau involved in the program. While the criteria for selecting a mixture of the 3 types of laboratories were different within each Bureau, the total number of laboratories tested were essentially equally divided between the Bureaus of Food, Veterinary Medicine, Drugs and Biologics.
A total of 67 experimental studies were inspected; 31 long-term, 23 short-term and 13 acute. Of those studies examined, 48 had been completed while 19 were still in progress.
The results of 39 inspections (3 Biologics laboratories were not considered appropriate for evaluation) were subdivided into two general categories: Laboratory Operations and Studies. Composite results were reported for each of the individual check-list items and multiple comparisons were presented with comments on unusual or unexpected findings.
Under the Laboratory Operation segment of the inspection, 23 industrial sponsors fared better (69%) than 11 contract facilities (56%) which in turn were better than 5 university laboratories (46%) when the final percentage of acceptible compliance answers were tabulated. Generally, facilities, animal care and personnel received higher scores, while scores for the quality assurance unit, test substance control and record retention were at the lower end of the grading range.
The results obtained from the Study segment in the inspection analysis, indicated a higher compliance in ongoing studies (73%) than in completed studies (57%). Among all the facilities inspected, animal care and test substance control ranked high on the compliance list, while the quality assurance unit and study conduct (protocol) were at the lower end of the scale.
When the overall Laboratory Operations and Study segment results were aggregated and evaluated for each specific GLP subsection, the following items ranked above 80% compliance; equipment design, access to professional assistance, animal care facilities, laboratory operation facilities, administrative and personnel facilities, reagents and solution, and animal supply facilities.
Likewise, those items ranked below 50% compliance were retention of records, maintenance and calibration of equipment, protocol, quality assurance unit, and mixture of substances with carrier.
While these inspections were carried out under the 'proposed' status of GLP regulations, the FDA did take action in certain cases as a result of specific findings. Letters have been issued to at least 3 laboratories indicating that certain studies would not be accepted. A data auditdnspection was initiated in at least 1 case to probe more deeply into"possib1e problems." It was anticipated that more action will be initiated as a direct result of these inspections.
The full text of this report may be obtained from the National Technical Information Service, 5285 Port Royal Road, Springfield. The ICD-0 is a supplement to the ninth revision of the "International Classification of Diseases (ICD-9) and contains coded nomenclature for classifying tumors by their anatomic site and morphologic type. The Morphology section has been included as the Neoplasm section of "Systematized Nomenclature of Medicine" (SNO-MED) recently published by the College of American Pathologists.
A combination alpha and 10 digit code number is used in the ICD-0 to classify all tumors. The first 14 digits indicate anatomical location of neoplasms as listed in Chapter I1 of the ICD-9. The next 4 digits indicate histologic type. A slash followed by the last two digits code for benign, malignant, grading and/or stage of differentiation.
As an example, the coding procedure would identify a welldifferentiated squamous cell carcinoma of the cervix as T-A special effort was made to list the terms used in the "International Histological Classification of Tumors" (Blue Books) also published by WHO. The IDC-O is said to be completely compatible with many entries contained in the "Manual of Tumor Nomenclature and Coding" (MOTNAC). as well as Morphology sections 8 and 9 of the "Systematized Nomenclature of Pathology" (SNOP).
The ICD-0 is available from all WHO Booksellers and the .29
